AR031071A1 - Derivados de la dihidrobenzodiazepina, un procedimiento para su preparacion , el uso de los mismos para preparar un medicamento y las composiciones farmaceuticas que contienen estos compuestos - Google Patents
Derivados de la dihidrobenzodiazepina, un procedimiento para su preparacion , el uso de los mismos para preparar un medicamento y las composiciones farmaceuticas que contienen estos compuestosInfo
- Publication number
- AR031071A1 AR031071A1 ARP000103436A ARP000103436A AR031071A1 AR 031071 A1 AR031071 A1 AR 031071A1 AR P000103436 A ARP000103436 A AR P000103436A AR P000103436 A ARP000103436 A AR P000103436A AR 031071 A1 AR031071 A1 AR 031071A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- alkyl
- optionally halogenated
- alkoxy
- heteroaryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- ZWWWYOKRVNYQHF-UHFFFAOYSA-N 2,3-dihydro-1h-1,2-benzodiazepine Chemical class C1=CCNNC2=CC=CC=C21 ZWWWYOKRVNYQHF-UHFFFAOYSA-N 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 abstract 1
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- -1 nitro, hydroxy Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/04—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describen derivados de la dihidrobenzodiazepina de formula (1) en la cual las líneas de punto indican la presencia eventual de una doble union; R1 representa (C1-18)alquilo eventualmente halogenado, (C1-18)alcoxi eventualmente halogenado, halogeno, nitro, hidroxi o (C6-18) arilo (eventualmente sustituido por (C1-10)alquilo eventualmente halogenado, (C1-12) alcoxi eventualmente halogenado, halogeno, nitro o hidroxi); n representa 0, 1, 2, 3 o 4; R2 y R3 representa independientemente uno del otro hidrogeno; (C1-18) alquilo eventualmente halogenado; (C1-18) alcoxi; (C6-18)arilo; (C6-18)aril-(C1-12)alquilo; heteroarilo; heteroaril (C1-12) alquilo; (C6-18) ariloxi; (C6-18)aril-(C1-12)alcoxi; heteroariloxi; o heteroaril (C1-12)alcoxi; en los cuales la parte arilo y heteroarilo de estos radicales son eventualmente sustituidas por halogeno, (C1-12)alcoxi eventualmente halogenado, (C1-12)alquilo eventualmente halogenado, nitro e hidroxi; R4 representa hidrogeno, (C1-18)alquilo o (C6-18)arilo, siendo dicho grupo arilo eventualmente sustituido por halogeno, (C1-12)alcoxi eventualmente halogenado, (C1-12)alquilo eventualmente halogenado, nitro o hidroxi; X representa S, O o ûNT, donde T representa un átomo de hidrogeno, (C1-12)alquilo, (C6-18)arilo, (C6-18)aril-(C1-12)alquilo o (C6-18)arilcarbonilo; Y R5, arilo, heteroarilo y heterociclo tienen los significados indicados en la memoria descriptiva. También se describe un procedimiento para preparar estos derivados de la dihidrobenzodiazepina y las composiciones farmacéuticas que los contienen. Finalmente se describe el uso de los compuestos de formula (1) para preparar un medicamento destinado a prevenir o tratar las dislipidemias, la arteriosclerosis, la diabetes y sus complicaciones. Estos compuestos son capaces de disminuir la secrecion de apo CIII.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9908714A FR2796070B1 (fr) | 1999-07-06 | 1999-07-06 | Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031071A1 true AR031071A1 (es) | 2003-09-10 |
Family
ID=9547763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000103436A AR031071A1 (es) | 1999-07-06 | 2000-07-06 | Derivados de la dihidrobenzodiazepina, un procedimiento para su preparacion , el uso de los mismos para preparar un medicamento y las composiciones farmaceuticas que contienen estos compuestos |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7323458B1 (es) |
| EP (1) | EP1189890B1 (es) |
| JP (1) | JP4699663B2 (es) |
| KR (1) | KR20020022763A (es) |
| CN (1) | CN1359377A (es) |
| AR (1) | AR031071A1 (es) |
| AT (1) | ATE323685T1 (es) |
| AU (1) | AU767016B2 (es) |
| BR (1) | BR0012169A (es) |
| CA (1) | CA2378165C (es) |
| CZ (1) | CZ20014604A3 (es) |
| DE (1) | DE60027429T2 (es) |
| ES (1) | ES2258975T3 (es) |
| FR (1) | FR2796070B1 (es) |
| HU (1) | HUP0201785A3 (es) |
| MX (1) | MXPA01013457A (es) |
| NO (1) | NO20020031L (es) |
| PL (1) | PL352333A1 (es) |
| RU (1) | RU2247115C2 (es) |
| SK (1) | SK19142001A3 (es) |
| WO (1) | WO2001002373A1 (es) |
| ZA (1) | ZA200201008B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10142660A1 (de) | 2001-08-31 | 2003-03-20 | Aventis Pharma Gmbh | Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
| US6677303B2 (en) | 2001-04-30 | 2004-01-13 | Syn X Pharma | Biopolymer marker indicative of disease state having a molecular weight of 1097 daltons |
| US20030013656A1 (en) * | 2001-05-03 | 2003-01-16 | Bing Wang | Pyruvate derivatives |
| DE10142722A1 (de) * | 2001-08-31 | 2003-03-27 | Aventis Pharma Deutschland GmbH, 65929 Frankfurt | C2-substituierte Indan-1-one und ihre Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE10142659A1 (de) | 2001-08-31 | 2003-03-20 | Aventis Pharma Gmbh | Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
| DE10142668A1 (de) | 2001-08-31 | 2003-03-20 | Aventis Pharma Gmbh | Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
| DE10320732A1 (de) * | 2003-05-05 | 2004-12-09 | Friedrich-Schiller-Universität Jena Büro für Forschungstransfer | Neue schnell wirkende Anästhetika und Verfahren zu ihrer Herstellung |
| AU2004257257B2 (en) * | 2003-07-10 | 2011-05-12 | Osi Pharmaceuticals, Inc. | Naphthylene derivatives as cytochrome P450 inhibitors |
| EP1648408A4 (en) * | 2003-07-23 | 2006-11-29 | Exelixis Inc | AZEPINE DERIVATIVES AS PHARMACEUTICAL AGENTS |
| WO2005035514A2 (en) * | 2003-10-08 | 2005-04-21 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
| US7662844B2 (en) | 2004-07-12 | 2010-02-16 | Osi Pharmaceuticals, Inc. | Naphthylene derivatives as cytochrome P450 inhibitors |
| EP1819669A2 (en) * | 2004-12-09 | 2007-08-22 | Kalypsys, Inc. | Novel inhibitors of histone deacetylase for the treatment of disease |
| GB0506133D0 (en) * | 2005-03-24 | 2005-05-04 | Sterix Ltd | Compound |
| KR102585191B1 (ko) * | 2020-08-25 | 2023-10-04 | 경기대학교 산학협력단 | 신규한 벤조디아제핀-3-온 유도체 및 이를 포함하는 당뇨병성 신경병증 치료 또는 예방용 약학적 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3780023A (en) * | 1972-06-30 | 1973-12-18 | J Suh | 2-aralkylamino-4,5-dihydro-3h-1,3-benzodiazepines |
| ES484553A1 (es) | 1978-10-05 | 1980-05-16 | Hoechst Ag | Un metodo para preparar 4-fenil-1,3-benzodiazepinas |
| US5260339A (en) | 1978-10-05 | 1993-11-09 | Hoechst-Roussel Pharmaceuticals Incorporated | 4-phenyl-1,3-benzodiazepines and 2-amino-α-phenylphenethylamines for treating convulsions and protecting neurons |
| FR2540871B1 (fr) * | 1983-02-16 | 1986-01-10 | Lipha | Amino-2 phenyl-5 benzodiazepines-1,3; procede de preparation et medicaments les contenant |
| FR2550199B1 (fr) * | 1983-08-02 | 1985-11-29 | Lipha | Imidazo et pyrimido (2,1-b) benzodiazepines-1,3, procedes de preparation et medicament les contenant |
| TW245719B (es) * | 1990-09-10 | 1995-04-21 | Sterling Winthrop Inc | |
| ZA956647B (en) * | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
| JPH08157369A (ja) * | 1994-10-07 | 1996-06-18 | Takeda Chem Ind Ltd | トリグリセライド低下剤 |
| JPH0987260A (ja) * | 1995-09-27 | 1997-03-31 | Takeda Chem Ind Ltd | 縮合環化合物とその用途 |
-
1999
- 1999-07-06 FR FR9908714A patent/FR2796070B1/fr not_active Expired - Fee Related
-
2000
- 2000-07-04 AT AT00945864T patent/ATE323685T1/de not_active IP Right Cessation
- 2000-07-04 HU HU0201785A patent/HUP0201785A3/hu unknown
- 2000-07-04 SK SK1914-2001A patent/SK19142001A3/sk unknown
- 2000-07-04 CN CN00809680A patent/CN1359377A/zh active Pending
- 2000-07-04 US US10/019,683 patent/US7323458B1/en not_active Expired - Fee Related
- 2000-07-04 PL PL00352333A patent/PL352333A1/xx unknown
- 2000-07-04 KR KR1020027000137A patent/KR20020022763A/ko not_active Ceased
- 2000-07-04 MX MXPA01013457A patent/MXPA01013457A/es unknown
- 2000-07-04 CA CA2378165A patent/CA2378165C/en not_active Expired - Fee Related
- 2000-07-04 RU RU2002102248/04A patent/RU2247115C2/ru not_active IP Right Cessation
- 2000-07-04 EP EP00945864A patent/EP1189890B1/fr not_active Expired - Lifetime
- 2000-07-04 BR BR0012169-0A patent/BR0012169A/pt not_active IP Right Cessation
- 2000-07-04 CZ CZ20014604A patent/CZ20014604A3/cs unknown
- 2000-07-04 ES ES00945864T patent/ES2258975T3/es not_active Expired - Lifetime
- 2000-07-04 JP JP2001507812A patent/JP4699663B2/ja not_active Expired - Fee Related
- 2000-07-04 AU AU59814/00A patent/AU767016B2/en not_active Ceased
- 2000-07-04 WO PCT/EP2000/006230 patent/WO2001002373A1/fr not_active Ceased
- 2000-07-04 DE DE60027429T patent/DE60027429T2/de not_active Expired - Lifetime
- 2000-07-06 AR ARP000103436A patent/AR031071A1/es unknown
-
2002
- 2002-01-04 NO NO20020031A patent/NO20020031L/no not_active Application Discontinuation
- 2002-02-05 ZA ZA200201008A patent/ZA200201008B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60027429T2 (de) | 2006-12-14 |
| WO2001002373A1 (fr) | 2001-01-11 |
| HUP0201785A3 (en) | 2003-02-28 |
| CA2378165A1 (en) | 2001-01-11 |
| AU767016B2 (en) | 2003-10-30 |
| PL352333A1 (en) | 2003-08-11 |
| US7323458B1 (en) | 2008-01-29 |
| ES2258975T3 (es) | 2006-09-16 |
| FR2796070B1 (fr) | 2003-02-21 |
| DE60027429D1 (de) | 2006-05-24 |
| ATE323685T1 (de) | 2006-05-15 |
| HUP0201785A2 (hu) | 2002-12-28 |
| EP1189890B1 (fr) | 2006-04-19 |
| WO2001002373A8 (fr) | 2001-06-14 |
| SK19142001A3 (sk) | 2002-06-04 |
| CZ20014604A3 (cs) | 2002-08-14 |
| KR20020022763A (ko) | 2002-03-27 |
| NO20020031D0 (no) | 2002-01-04 |
| MXPA01013457A (es) | 2002-07-22 |
| CA2378165C (en) | 2010-08-17 |
| EP1189890A1 (fr) | 2002-03-27 |
| JP4699663B2 (ja) | 2011-06-15 |
| ZA200201008B (en) | 2003-08-27 |
| BR0012169A (pt) | 2002-03-19 |
| FR2796070A1 (fr) | 2001-01-12 |
| AU5981400A (en) | 2001-01-22 |
| RU2247115C2 (ru) | 2005-02-27 |
| NO20020031L (no) | 2002-03-05 |
| CN1359377A (zh) | 2002-07-17 |
| JP2003503483A (ja) | 2003-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031071A1 (es) | Derivados de la dihidrobenzodiazepina, un procedimiento para su preparacion , el uso de los mismos para preparar un medicamento y las composiciones farmaceuticas que contienen estos compuestos | |
| AR015769A1 (es) | Derivados de imidazo piridina que inhiben la secrecion de acido gastrico, procedimiento para la preparacion de dichos derivados, composicion farmaceutica, uso de dichos derivados para la preparacion de medicamentos, y compuestos intermediarios. | |
| AR011134A1 (es) | Derivados de imidazo piridina substituidos para la inhibicion de la secrecion de acido gastrico; una sal del mismo, procedimiento para su preparacion, formulacion farmaceutica que los contiene y el uso de dicho compuesto para la manufactura de un medicamento | |
| AR034283A1 (es) | Compuestos heterociclilindazol y azaindazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| BR0208678A (pt) | Composto, composição farmacêutica, uso de um composto | |
| NO20015379D0 (no) | Indolinderivater som progesteronantagonister | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| AR023423A1 (es) | Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos | |
| ATE286501T1 (de) | Pyrimidinderivate | |
| CY1110332T1 (el) | Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους | |
| ATE302775T1 (de) | Carbolinderivate | |
| BR0016543A (pt) | Novos derivados de piperidina e piperazina | |
| MX9704777A (es) | Compuestos espiro tetraciclicos, procedimiento para su preparacion y composiciones que los contienen. | |
| ITRM20010356A1 (it) | "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. | |
| ATE109481T1 (de) | Diazinderivate als angiotensin ii rezeptor antagonisten. | |
| AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
| TR200100698T2 (tr) | 5-HT4 alıcı-Antagonistleri olarak Dihidrobenzodioksin Karboksamit ve Keton türevleri | |
| PA8495101A1 (es) | Derivados de 13-metileritromicina | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR048567A1 (es) | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. | |
| ATE235476T1 (de) | Thiazolidindione derivate, ihre herstellung und verwendung | |
| ATE346067T1 (de) | Carbolinderivate | |
| ATE300541T1 (de) | Pyrazolopyridinderivate | |
| AR017189A1 (es) | Antagonistas del receptor de trombina triciclico sustituido, composicion farmaceutica que lo contiene y su uso para la manufactura de un medicamento | |
| ES2160602T3 (es) | Derivados de quinolona y acridinona para el tratamiento de la incontinencia urinaria. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |